BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

HIV clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for HIV: 85 (30 sponsors; 18 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 20.6, rank 28 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 19, Phase 2 30, Phase 3 23, Phase 4 3, N/A 8.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
ViiV Healthcare27P2 6, P1 12, P3 975
Merck Sharp & Dohme LLC MRK11P2 4, P3 6, P1 131
Gilead Sciences GILD14P1 2, P2 4, P3 5, P4 2, NA 130
Jiangsu Aidea Pharmaceutical Group Co., Ltd. new entrant2P2 1, P3 120
Biofabri, S.L1P3 100
Serum Institute of India Pvt. Ltd.1P3 101
BioNTech SE BNTX3P1 2, P2 110
bioLytical Laboratories2NA 202
Frantz Viral Therapeutics, LLC2P2 202
Jecho Biopharmaceuticals Co., Ltd.2P1 1, P2 101
American Gene Technologies International Inc. AIG1NA 100
American Laboratory Products Company AIG1NA 101
Calimmune, Inc.1NA 100
Cell Energy Life Sciences Group Co. LTD1P2 100
Code Pharma1P2 100
Epividian1NA 100
Estrella Immunopharma, Inc. ESLA1P2 100
GlaxoSmithKline1P2 101
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair1EARLY_P1 100
Henan Genuine Biotech Co., Ltd.1P2 101
Immuno Cure Holding (HK) Limited1P1 101
Liaoning Chengda Biotechnology CO., LTD new entrant1P4 110
MagIA Diagnostics1NA 100
MGB Pharma1P2 100
Mundipharma Research Limited1P2 100

New-entrant sponsors: Jiangsu Aidea Pharmaceutical Group Co., Ltd., Liaoning Chengda Biotechnology CO., LTD.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2UBP Greater China (Shanghai) Co., LtdNCT04985890 A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral ReservoirHIV-1-infectionnot yet recruiting20
2026-12 est.P2Henan Genuine Biotech Co., Ltd.NCT07308782 A Phase Ⅱa Clinical Study of CL-197 CapsulesHIV-1 Infectionrecruiting24
2027-02-12 est.P1/P2Jecho Biopharmaceuticals Co., Ltd.NCT07579741 A Study to Evaluate JL18008 in Subject With HIV Immunological Non-RespondersHIV Infectionsrecruiting30

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-03P2/P3Gilead Sciences GILDNCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuHIV-1-Infectionterminated80
2026-09-09P2ViiV HealthcareNCT06741397 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month DoHIV Infectionsactive not recruiting229
2026-08-19P3ViiV HealthcareNCT06694805 A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1HIV Infectionsactive not recruiting326
2026-08-18P2Janssen Sciences Ireland UCNCT02494986 A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesHuman Immunodeficiency Virus Type 1completed48
2026-07-27P2Gilead Sciences GILDNCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting181
2026-07-22P2Gilead Sciences GILDNCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting253
2026-07-10 est.P1/P2Shanxi Kangbao Biological Product Co., Ltd.NCT07433387 Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected IndividualsHIVrecruiting30
2026-06-30 est.P3United BioPharma UTHRNCT04406727 UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 InfectionHIV-1 Infectionunknown50
2026-06-01 est.P1/P2ViiV HealthcareNCT05674656 Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsHIV Infectionsrecruiting20
2026-05-28P2Gilead Sciences GILDNCT06513312 Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting268
2026-05-27P2ViiV HealthcareNCT05996471 A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With HuHIV Infectionsactive not recruiting185

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "HIV"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.